Loading data for PVLA — first visit, this takes a few seconds.
Palvella Therapeutics, Inc. (PVLA)
NasdaqGM: PVLA
· Real-Time Price · USD
152.59
+2.62 (1.75%)
At close: Sep 02, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Palvella Therapeutics, Inc. (PVLA) Stock Price, Analysis & Data
1.75% (1D)
| Bid | 111.17 |
| Market Cap | 2.2B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.7M |
| 0.00 | |
| -4.86 | |
| n/a | |
| -20.4 | |
| P/B (ttm) | 10.15 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 11, 2026 |
| Ask | 195.41 |
| Volume | 245,677 |
| Avg. Volume (20D) | 256,473 |
| Open | 147.95 |
| Previous Close | 149.97 |
| Day's Range | 143.47 - 152.89 |
| 52-Week Range | 50.82 - 161.38 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformation...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2015
Employees 29
Stock Exchange NasdaqGM
Ticker Symbol PVLA
Website https://palvellatx.com
Financial Performance
In 2025, Palvella Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -41.72M, an increase of 139.27%.
Financial StatementsEarnings Surprise
Palvella Therapeutics has released their quarterly earnings on Aug 4, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.52 misses estimates by -0.37, with -76.74% YoY decline.
Palvella Therapeutics, Inc. is scheduled to release its earnings on Nov 11, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2